Tokyo, Feb. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060775) titled 'Nova-sTAR PIONEER-JP-Panel Interview of ONcology practice with Experience of TAR-200 in Japan' on Feb. 27.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - Bladder cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To describe early experiences regarding TAR-200 insertion, removal, and patient care from physicians with experience treating patients with TAR-200 in clinical trials. Based on the findings, the study aims to identify clinical best practices, barriers, and future care models to support the...